Pre-Surgery Medication: A Game Changer
- LONDON (May 17, 2025) — A new study suggests a potential breakthrough in the treatment of triple-negative breast cancer, an aggressive form of the disease.
- Triple-negative breast cancer accounts for approximately 15% of breast cancer cases in France, where roughly 61,000 diagnoses are made annually.
- The disease often affects younger women and those with BRCA1 and BRCA2 gene mutations,which predispose them to hereditary cancers.
Olaparib Shows Promise in Treating Triple-Negative Breast Cancer
Table of Contents
- Olaparib Shows Promise in Treating Triple-Negative Breast Cancer
- Olaparib Shows Promise in Treating Triple-Negative Breast Cancer: Your Questions Answered
- What is Triple-Negative Breast Cancer?
- why is Triple-Negative Breast Cancer Challenging to Treat?
- What is the Standard Treatment for Triple-Negative Breast Cancer?
- what is Olaparib and How is it Being Used to Treat TNBC?
- How Does Olaparib Work?
- What Did the “Partner” Trial Reveal About Olaparib?
- What Are the Key Differences Between the Treatment Groups?
- Who Led the ”Partner” Trial and Where Was it Conducted?
- What Are the Next steps for Olaparib in TNBC Treatment?
- Could Olaparib Be Used to Treat Other cancers?
LONDON (May 17, 2025) — A new study suggests a potential breakthrough in the treatment of triple-negative breast cancer, an aggressive form of the disease. Researchers from the University of Cambridge have found that adding the drug Olaparib to chemotherapy before surgery significantly improved survival rates in a trial group.
Triple-negative breast cancer accounts for approximately 15% of breast cancer cases in France, where roughly 61,000 diagnoses are made annually. This type of cancer is notoriously difficult to treat because it lacks receptors for estrogen and progesterone, and does not overexpress the HER2 protein. These characteristics render it unresponsive to hormonal therapies and treatments targeting HER2.
The disease often affects younger women and those with BRCA1 and BRCA2 gene mutations,which predispose them to hereditary cancers. The standard treatment involves chemotherapy and immunotherapy to shrink the tumor, followed by surgical removal. The subsequent three years are critical, with a high risk of recurrence and mortality.
Olaparib Boosts Survival Rates
The “Partner” trial, led by University of Cambridge researchers, explored the impact of adding Olaparib to chemotherapy before surgery. Olaparib has demonstrated effectiveness in preventing recurrence in women with BRCA mutations when administered post-operatively.Though,this trial investigated its use prior to surgery.
In the study,patients received Olaparib for 12 weeks before surgery,in conjunction with chemotherapy. the results, published May 13 in Nature Communications, indicated that among 39 patients who received both chemotherapy and Olaparib, only one experienced a recurrence, resulting in a 100% survival rate over three years.
In contrast, the control group, consisting of 45 patients who received only chemotherapy, had an 88% survival rate after three years. Nine patients in the control group experienced a relapse, and six died.
Potential Request to Other Cancers?
Prof. Jean Abraham, head of the trial at Addenbrooke Hospital, part of Cambridge University Hospitals (CUH), expressed enthusiasm about the findings. It is indeed rare to obtain a 100 % survival rate in a study like this, and for these types of aggressive cancer… we are extremely eager about the potential of this new approach,because it is crucial to find a way to treat and hope to cure patients diagnosed with cancers linked to the BRCA1 and BRCA2 genes.
While these results are promising, larger-scale studies are needed to validate them. Researchers speculate that this treatment approach could potentially be applied to other cancers involving BRCA genes, such as ovarian, prostate, and pancreatic cancers.
How Olaparib Works
Olaparib is a PARP inhibitor. PARP proteins, along with BRCA proteins, play a role in DNA repair. In triple-negative breast cancer, mutated BRCA1 and BRCA2 genes are unable to perform their DNA repair function. Consequently,the mutated cells become reliant on PARP for repair.
PARP inhibitors prevent cancer cells from utilizing PARP, leading to an accumulation of unrepairable DNA errors. This ultimately causes the death of the cancer cells.
Olaparib Shows Promise in Treating Triple-Negative Breast Cancer: Your Questions Answered
Here’s a breakdown of this promising treatment for triple-negative breast cancer, explained in a Q&A format:
What is Triple-Negative Breast Cancer?
Triple-negative breast cancer (TNBC) is a type of breast cancer that lacks three key receptors: estrogen receptors, progesterone receptors, and the HER2 protein. This means common hormonal therapies and HER2-targeting treatments used for other breast cancers are ineffective.
why is Triple-Negative Breast Cancer Challenging to Treat?
TNBC’s unique characteristics make it hard to treat. Because it lacks the receptors targeted by standard therapies,treatment options are limited. it’s often aggressive and tends to affect younger women and those with BRCA1 and BRCA2 gene mutations.
What is the Standard Treatment for Triple-Negative Breast Cancer?
The standard treatment for TNBC typically involves:
Chemotherapy: To shrink the tumor.
Immunotherapy: Often used in conjunction with chemotherapy.
Surgery: To remove the tumor.
The three years following treatment are critical due to the high risk of recurrence and mortality.
what is Olaparib and How is it Being Used to Treat TNBC?
Olaparib is a drug that belongs to a class called PARP inhibitors. In a recent study by researchers from the University of Cambridge, Olaparib was added to chemotherapy before surgery.
How Does Olaparib Work?
Olaparib works by targeting PARP proteins, which play a role in DNA repair.In TNBC, particularly in those with BRCA1 and BRCA2 gene mutations, the cancer cells rely on PARP for DNA repair. Olaparib prevents cancer cells from using PARP,leading to an accumulation of DNA errors and,ultimately,cell death.
What Did the “Partner” Trial Reveal About Olaparib?
The “Partner” trial, conducted by the University of Cambridge, investigated the impact of adding Olaparib to chemotherapy before surgery. The findings,published in Nature Communications,showed extraordinary results:
Patients Receiving Olaparib and Chemotherapy: Of 39 patients,only one experienced a recurrence,resulting in a 100% survival rate over three years.
Patients receiving Chemotherapy Only (Control Group): Out of 45 patients, the survival rate was 88% after three years. Nine patients had a relapse,and six died.
What Are the Key Differences Between the Treatment Groups?
The ”partner” trial showed a marked difference in outcomes between the two treatment groups. Here’s a comparison:
| treatment Group | Survival Rate (3 years) | Recurrence Rate |
|---|---|---|
| Chemotherapy + Olaparib (39 Patients) | 100% | 1 patient |
| Chemotherapy Only (45 Patients) | 88% | 9 patients |
Who Led the ”Partner” Trial and Where Was it Conducted?
The trial was led by Prof. Jean Abraham, head of the trial at Addenbrooke Hospital, part of Cambridge University Hospitals (CUH).
What Are the Next steps for Olaparib in TNBC Treatment?
While the results are promising, larger-scale studies are needed to validate these findings. Researchers are optimistic that this new approach could improve treatment outcomes for patients diagnosed with cancers linked to the BRCA1 and BRCA2 genes.
Could Olaparib Be Used to Treat Other cancers?
Researchers are speculating that this treatment approach could perhaps be applied to other cancers involving BRCA genes, such as:
Ovarian cancer
Prostate cancer
Pancreatic cancer